The gene editing market is on the verge of a groundbreaking transformation, poised to surge from USD 5.3 billion in 2023 to a staggering USD 10.6 billion by 2028, at an impressive CAGR of 15.0%. At its core, gene editing, also known as genome engineering, involves the precise manipulation of an organism’s or cell’s DNA, including insertions, deletions, or replacements, at specific genomic sites. This extraordinary capability is achieved through the utilization of innovative genome-editing tools, such as CRISPR, TALEN, and ZFN. This rapidly evolving field is reshaping the landscape of genetic modification, offering unprecedented possibilities for tailored interventions in the genomes of animals, plants, and human cells.

Download PDF Brochure:

A Fragmented Yet Flourishing Landscape

The global genome editing market is characterized by its high degree of fragmentation, with a multitude of players vying for prominence. Notable contenders in this dynamic market include Merck KGaA, Thermo Fisher Scientific, GenScript, Agilent Technologies, PerkinElmer, Lonza, Tecan Life Sciences, Sangamo Therapeutics, Editas Medicine, CRISPR Therapeutics AG, Precision Biosciences, Cellectis S.A., Intellia Therapeutics, Bluebird Bio, Regeneron Pharmaceuticals, AMSBIO, Creative Biogene, Synthego Corporation, and Beam Therapeutics Inc. The market also boasts other innovative companies such as Caribou Biosciences, OriGene Technologies, New England Biolabs, Inscripta, and Mammoth Biosciences.

Key Players in the Gene Editing Market

Let’s delve into the strategies and contributions of three major players shaping the gene editing market:

  1. Thermo Fisher Scientific (US): Thermo Fisher Scientific is a powerhouse in the gene editing arena, offering a comprehensive and integrated portfolio of solutions and services. With a strong emphasis on clinical science, laboratory research, and analysis, the company has carved a niche for itself in gene modification and precision genome editing. Thermo Fisher Scientific’s high-efficiency delivery systems facilitate the development of gene expression systems, modified genes, and stable engineered cell lines. The company’s genome editing technologies, including CRISPR-Cas9 and TAL effectors, are accessible through licensing, supporting various applications such as contract manufacturing services, research, vaccine development, animal health, biofuels, and diagnostics.
  2. Merck KGaA (Germany): Merck KGaA, one of the top contenders in the genome editing market, collaborates closely with pharmaceutical and biotechnology companies engaged in genomic and personalized medicine. The company’s strength lies in licensing its proprietary editing technology to bolster its market presence. In a significant move, Merck signed a collaboration and license agreement in March 2022 with BetterSeeds, an Israeli company focused on developing new plant breeds using CRISPR technology. This strategic agreement, facilitated through Merck’s Life Science division, MilliporeSigma, aims to expand the reach of its proprietary CRISPR Cas9 technology, further solidifying its position in the gene editing domain.
  3. GenScript (China): GenScript, a prominent player in the gene editing market, boasts a comprehensive portfolio of products and services dedicated to gene editing. The company’s strong foothold in CRISPR technology is the result of substantial investments in research and development. GenScript offers validated CRISPR products, services, and resources through its partnership with the Broad Institute of MIT and Harvard, led by renowned scientist Feng Zhang. GenScript’s expertise in CRISPR extends across cell therapy, CAR-T cell therapy, and gene therapy applications, making it a formidable competitor in the market.

Get More Insights – Download PDF Sample:


The gene editing market is at the forefront of revolutionizing genetic modification, with a promising future marked by unprecedented growth. Key players like Thermo Fisher Scientific, Merck KGaA, and GenScript are leading the charge, offering innovative solutions and technologies that are reshaping the landscape of genetic engineering. As the gene editing field continues to evolve, these companies are poised to harness the immense potential for tailored genomic interventions, ushering in a new era of precision medicine and biotechnology.

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

© 2024 Crivva. All Rights Reserved.